The introduction of selective tyrosine kinase inhibitors (TKIs) for the treatment of various malignancies has positively changed the management of these diseases. However, this therapy fails in some cases due to induction of resistance to TKIs. Several possible mechanisms of resistance to TKIs have been described. Mutation in the kinase domain is an important mechanism of resistance, because it decreases the receptor affinity of the TKI. Further elucidation of mechanisms of resistance and determination of their clinical relevance is essential for development of rational therapies for TKI-resistant tumours. Probably none of the mechanisms is solely responsible for the induction of resistance. Most likely, resistance is caused by complex coincidence of several mechanisms. Therefore, combination therapy with TKIs seems suitable as an initial treatment strategy.
|Vertaalde titel van de bijdrage||Resistance against tyrosine kinase inhibitors|
|Nummer van het tijdschrift||30-31|
|Status||Gepubliceerd - 24 jul. 2009|